Back pain in young patients

Abstract

Osteoarthritis (OA) of the facet joint (FJ) plays a significant genesis role of chronic lower back pain (cLBP) in 15–41%. OA FJ of lumbar spine occurs in 24–82% of younger people than 40 years. It has been shown that the ingestion of the "back pain" symptom at a young age in the subsequent (after 10–15 years) leads to the formation of cLBP, with a recurrent course, while OA FJ is noted in the overwhelming number of patients studied. An important aspect in the tactics choice of back pain in young patients treatment is the chronization prevention and pain syndrome relapses. In LBP treatment of against the background of OA FJ, it is recommended to use standard scheme therapy: at the first stage – injectable and oral nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, B vitamins, as well as injectable Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) – chondroitin sulfate (CS), glucosamine sulfate (GS), undenatured collagen II type (UC-II), as well as their combinations; at the second stage – oral SYSADOA (CS, GS, UC-II, as well as their combinations) and topical NSAIDs. SYSADOA have symptom- and structural-modifying effects. As a promising direction of OA therapy, the use of drugs with already proven efficacy containing CS, GS, in combination with a new molecule – UC II is considered.